Compare Amphastar Pharmaceuticals Inc (AMPH) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.54 (market cap $826.08M), while Teradyne, Inc. trades at $343.6 (market cap $56.29B). The key difference: Teradyne, Inc. is far larger — about 68.1× Amphastar Pharmaceuticals Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TER | |
|---|---|---|
Market Cap | $826.08M | $56.29B |
Sector | Health | Technology |
52-Week High | $30.81 | $483.84 |
52-Week Low | $16.87 | $90.15 |
Enterprise Value | $1.22B | $56.13B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Teradyne (TER) trades at $359.60, down 0.87% amid a bearish technical signal, though it remains supported by strong fundamentals including a 22.55% net income margin and consistent earnings beats. Recent news highlights AI-driven data center demand boosting revenue, with Q2 2026 EPS expected at $2.04. The company maintains robust profitability metrics like 28.75% ROE, but faces headwinds from negative net cash flow trends and elevated valuation ratios (P/E 66.72).
Outlook: TER's AI and robotics exposure offers growth potential, with a consensus price target of $453.60 implying 26% upside. Risks include semiconductor cycle volatility and high valuations. Analyst sentiment is bullish (64.5% buy ratings), but investors should monitor execution on Q2 earnings and cash flow improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
